Vectura has agreed to a £1.55 per share takeover by US private investment company Carlyle, which values the UK drug delivery specialist at £958 million ($1.4 billion). The acquisition of one ...

Philip Morris Intl. expands into cannabis via Avicanna partnership, focusing on medical research and innovation: How this move aligns with its long-term strategy.

Vectura's LOMI device has several potential advantages over traditional inhaler technology. Foil blister strips of up to 60-metered doses can be housed within the device which are then ...

Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, ...

Wiltshire inhaler firm Vectura, which was behind the proposals, was snapped up last week by US manufacturer Molex - the parent firm of contract development organisation Phillips Medisize.